Prevention of ST
From Wikidoc - Reading time: 5 min
|
WikiDoc Resources for Prevention of ST |
|
Articles |
|---|
|
Most recent articles on Prevention of ST Most cited articles on Prevention of ST |
|
Media |
|
Powerpoint slides on Prevention of ST |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Prevention of ST at Clinical Trials.gov Trial results on Prevention of ST Clinical Trials on Prevention of ST at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Prevention of ST NICE Guidance on Prevention of ST
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Prevention of ST Discussion groups on Prevention of ST Patient Handouts on Prevention of ST Directions to Hospitals Treating Prevention of ST Risk calculators and risk factors for Prevention of ST
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Prevention of ST |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editors-In-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview[edit | edit source]
The risk of stent thrombosis is reduced with the use of combined antiplatelet therapy.
- There are better outcomes noted with the use of aspirin plus ticlopidine or clopidogrel than with aspirin plus warfarin or aspirin alone[1][2][3][4][5].
- Preliminary evidence suggests prasugrel resulted in fewer ischaemic outcomes including stent thrombosis than with standard clopidogrel[6].
Clinical trial data[edit | edit source]
- In STARS trial[1], studying 1653 patients showed superiority of aspirin and ticlopidine over combination of aspirin and warfarin or aspirin alone for reducing subacute stent thrombosis, although there were more hemorrhagic complications than with aspirin alone.
- A similar benefit for combined aspirin plus ticlopidine was noted in another randomized controlled trial[2].
- Results from double blinded randomized studies- PCI-CURE trial[7], analyzing 2658 patients and CREDO trial[8], analyzing 2116 patients, revealed the benefit of clopidogrel therapy increased with time and provide evidence for at least one year therapy in patients with BMS. However both the studies did not evaluate DES.
- TRITON TIMI-38[6]trial analyzing 12,844 patients who underwent stenting for ACS revealed intensive antiplatelet therapy with prasugrel resulted in fewer ischaemic outcomes including stent thrombosis than with standard clopidogrel.These findings were statistically robust irrespective of stent type, and the data affirm the importance of intensive platelet inhibition in patients with intracoronary stents.
Coronary stent thrombosis prevention[edit | edit source]
The 2008 American College of Chest Physician illustrates the following guidelines for primary and secondary prevention of coronary artery disease[9].
| “ |
1. For long term treatment of patients after PCI, we recommend aspirin at a dose of 75–100 mg/d (Grade 1A). 2. For patients who undergo bare metal stent placement, we recommend the combination of aspirin and clopidogrel for at least 4 weeks (Grade 1A). 3. For patients undergoing PCI with BMS placement following ACS, we recommend 12 months of aspirin (75–100 mg/d) plus clopidogrel (75 mg/d) over aspirin alone (Grade 1A). 4. For patients undergoing PCI with a DES, we recommend aspirin (75–100 mg/d) plus clopidogrel (75 mg/d for at least 12 months) [Grade 1A for 3 to 4 months; Grade 1B for 4 to 12 months]. Beyond 1 year, we suggest continued treatment with aspirin plus clopidogrel indefinitely if no bleeding or other tolerability issues (Grade 2C). |
” |
References[edit | edit source]
- ↑ 1.0 1.1 Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK; et al. (1998). "A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators". N Engl J Med. 339 (23): 1665–71. doi:10.1056/NEJM199812033392303. PMID 9834303.
- ↑ 2.0 2.1 Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M; et al. (1996). "A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents". N Engl J Med. 334 (17): 1084–9. doi:10.1056/NEJM199604253341702. PMID 8598866.
- ↑ Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H; et al. (1998). "Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study". Circulation. 98 (16): 1597–603. PMID 9778323.
- ↑ Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A; et al. (1998). "Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)". Circulation. 98 (20): 2126–32. PMID 9815866.
- ↑ Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, CLASSICS Investigators (2000). "Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS)". Circulation. 102 (6): 624–9. PMID 10931801.
- ↑ 6.0 6.1 Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP; et al. (2008). "Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial". Lancet. 371 (9621): 1353–63. doi:10.1016/S0140-6736(08)60422-5. PMID 18377975. Review in: ACP J Club. 2008 Sep 16;149(3):12
- ↑ Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK; et al. (2001). "Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study". Lancet. 358 (9281): 527–33. PMID 11520521.
- ↑ Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C; et al. (2002). "Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial". JAMA. 288 (19): 2411–20. PMID 12435254. Review in: ACP J Club. 2003 Jul-Aug;139(1):2
- ↑ Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA; et al. (2008). "The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 776S–814S. doi:10.1378/chest.08-0685. PMID 18574278.
EncycloReader
is supported by the 
KSF